7 European Projects Found
Searched on 125080 European Projects
FINISHED
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Start date: Jan 1, 2015, End date: Dec 31, 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Read Project
34
Partners Participants
FINISHED
European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)
Start date: Apr 1, 2012, End date: Mar 31, 2017,
...ologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenot ...
Read Project
29
Partners Participants
FINISHED
New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours (PREDECT)
Start date: Feb 1, 2011, End date: Apr 30, 2016,
... and AstraZeneca, and the managing entity of IMI JU funding is the University of Helsinki. The team assembles world-class biologists, clinicians and computational scientists from 8 prestigious EU institutes, 3 SMEs and 8 EFPIA members to develop and critically assess models for target validation. The interaction between pharmaceutical and academic participants will be proactive, through postdoc co ...
Read Project
23
Partners Participants
FINISHED
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)
Start date: Jan 1, 2010, End date: Dec 31, 2015,
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Read Project
38
Partners Participants
FINISHED
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)
Start date: Feb 1, 2010, End date: Sep 30, 2015,
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Read Project
23
Partners Participants
FINISHED
Novel Methods leading to New Medications in Depression and Schizophrenia (NEWMEDS)
Start date: Sep 1, 2009, End date: Feb 28, 2015,
...s and finding biologically-homogenous groups of patients will overcome existing limitations in target identification, early triage and clinical trials. To implement this idea six leading European institutions and two SMEs will partner with the EFPIA to: a) develop animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive functi ...
Read Project
20
Partners Participants
FINISHED
Genomic Instability in Cancer and Precancer (GENICA)
Start date: Jan 1, 2008, End date: Dec 31, 2010,
"Genomic instability is a characteristic of practically all human cancers. Recent results generated by members of this Consortium suggest that signs of genomic instability are evident from the very beginning of human cancer development, even in precancerous lesions. In these early lesions, the genomic instability affects primarily specific genomic loci, called common fragile sites. Because common ...
Read Project
